Back

The Journal of Infectious Diseases

137 training papers 2019-06-25 – 2026-03-07

Top medRxiv preprints most likely to be published in this journal, ranked by match strength.

1
An Fc receptor and IgA functional signature identifies TB disease in children living with HIV
2026-02-10 hiv aids 10.64898/2026.02.08.26345833
#1 (17.2%)
Show abstract

BackgroundTuberculosis (TB) is a leading cause of morbidity and mortality among children living with HIV (CLHIV). Poor diagnostic performance is a significant contributor. Serological assays that determine levels of Mycobacterium tuberculosis reactive antibodies inconsistently detect TB. However, antigen-specific antibody Fc receptor engagement and effector functions are promising biomarkers of TB disease. MethodsThis study evaluated serum from a well-characterized cohort of Kenyan CLHIV via tw...

2
Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan Africa: A Prospective, Multicenter Analysis from Uganda
2026-01-02 hiv aids 10.64898/2025.12.31.25343299
#1 (14.8%)
Show abstract

ObjectiveSevere tuberculosis (TB) is a major cause of critical illness and death in people living with HIV (PLWH) worldwide. Despite this, the immunopathology of severe HIV-associated TB (HIV/TB) is poorly understood. We aimed to identify an immunopathologic signature of severe HIV/TB in sub-Saharan Africa. Design and SettingWe analyzed proteomic data from two prospective observational cohorts of adults hospitalized with severe undifferentiated infection in Uganda: an urban discovery cohort (En...

3
Planning robust clinical trials for Shigella vaccines: A simulation-based evaluation of the impact of naturally-acquired immunity on vaccine performance
2025-12-12 epidemiology 10.64898/2025.12.11.25341848
#1 (14.4%)
Show abstract

BackgroundSeveral Shigella vaccine candidates are in late stages of development, and the design of large Phase 3 trials in target populations is underway. Immunologic catch up by unvaccinated infants to vaccinated infants, which is determined by the trial site-specific force of infection, may modify the vaccine efficacy (VE) estimates observed in such trials. To set expectations and support optimal planning of future Shigella vaccine trials, we aimed to quantify the potential bias of VE estimate...

4
Imported malaria predominates in near-elimination settings in Southwestern Uganda
2026-01-27 infectious diseases 10.64898/2026.01.25.26344810
#1 (14.1%)
Show abstract

BackgroundMalaria transmission in southwestern Uganda is low, but persists despite ongoing control efforts. Identifying whether infections are locally sustained or imported by travelers is critical for guiding interventions. We integrated epidemiologic surveillance with parasite genomics to characterize imported malaria episodes at three health facilities in southwestern Uganda. MethodsBetween January 2023 and June 2024, we enrolled microscopy-confirmed malaria cases at three health facilities,...

5
Plasmodium falciparum infectious reservoir in a rural setting in Burkina Faso: a two-year cohort study
2026-01-11 epidemiology 10.64898/2026.01.09.26343521
#1 (11.8%)
Show abstract

BackgroundMalaria caused by Plasmodium falciparum remains a major global health challenge. Although clinical disease results from asexual blood-stage replication, transmission depends on gametocyte carriage. We characterized the seasonal dynamics of the human infectious reservoir in a rural high-transmission setting in Burkina Faso. MethodsWe conducted a 2-year cohort study (2019-2020) including 871 individuals of all ages from four villages in the Nanoro health district. Participants were acti...

6
Estimating enteric fever seroincidence in Bangladesh using rapid serosurveys
2026-01-13 infectious diseases 10.64898/2026.01.11.26343883
#1 (11.2%)
Show abstract

BackgroundEnteric fever, caused by Salmonella Typhi or Paratyphi, is a major public health issue in low-and middle-income countries. Accurate burden estimation is hampered by limited microbiological facilities and low sensitivity of blood culture tests. Serosurveillance offers a scalable alternative to address these challenges. This study estimated the seroincidence of enteric fever in Bangladesh using cross-sectional rapid serosurveys. MethodsSchool-based surveys (January-June 2022) were condu...

7
Estimating the Transmission Potential of Symptomatic and Asymptomatic Cholera Cases from Household Microbiological and Clinical Data
2026-01-11 epidemiology 10.64898/2026.01.09.26343785
#1 (10.5%)
Show abstract

BackgroundIn Bangladesh, cholera treatment focuses on acute watery diarrhea in symptomatic cases at health facilities, though asymptomatic infections are common. Understanding the role of asymptomatic infections in transmission is crucial for designing appropriate control strategies in this setting. MethodsWe utilized data from household studies conducted in Dhaka, Bangladesh during 2006-2018 where a symptomatic confirmed cholera case and their household contacts were followed for thirty days. ...

8
Safety and Immunogenicity of 20-Valent PCV According to Number and Timing of Primary Series Doses
2026-01-02 infectious diseases 10.64898/2025.12.23.25342907
#1 (8.9%)
Show abstract

BackgroundThe number and timing of pneumococcal conjugate vaccine (PCV) primary doses can impact infant immune responses. This descriptive post hoc analysis evaluates the immunogenicity of the 20-valent PCV (PCV20) by vaccination timing in healthy infants in 2 key phase 3 trials. MethodsImmunogenicity endpoints from study B7471012 comparing PCV20 to 13-valent PCV (PCV13) in a 2+1 schedule were examined by timing of vaccination subgroup; the 2,4m subgroup (participants vaccinated at 2, 4, and 11...

9
Temporal trends in Plasmodium vivax diversity in eastern Cambodia evidence declining transmission
2026-03-04 infectious diseases 10.64898/2026.03.03.26346840
Top 0.1% (8.5%)
Show abstract

BackgroundElimination of Plasmodium vivax is challenging due to its dormant liver stages (hypnozoites), which can reactivate weeks or months after the primary infection, causing relapses and ongoing transmission of the parasite. Despite these challenges, P. vivax clinical case numbers have declined over the past decade in Cambodia. We used parasite genotyping to assess whether the decline in case numbers was reflected in parasite diversity and relatedness as a proxy to transmission. MethodsGeno...

10
Peak Nasal SARS-CoV-2 and Influenza Viral Loads Relative to Symptom Onset, 2022-2025: Impact of Vaccination and Implications for Multiplexed Testing
2025-12-30 infectious diseases 10.64898/2025.12.23.25342938
Top 0.1% (8.0%)
Show abstract

BackgroundWe previously reported that nasal SARS-CoV-2 viral loads (VL) peaked around the fourth day of symptoms in highly immune adults sampled April 2022 - April 2023, while influenza A VL peaked soon after symptom onset. We hypothesized that SARS-CoV-2 kinetics may have changed due to reduced COVID-19 incidence and altered vaccination patterns. Understanding how viral kinetics evolve over time is essential to inform testing strategies. MethodsParticipants with symptomatic upper respiratory i...

11
The Decline in Influenza Antibody Titers and Modifiers of Vaccine Immunity from over Ten Years of Serological Data
2026-01-15 infectious diseases 10.64898/2026.01.07.25342310
Top 0.2% (7.7%)
Show abstract

Annual influenza vaccination is the cornerstone for seasonal protection, yet antibody responses are highly variable across individuals and over time. To systematically assess the determinants of this heterogeneity, we compiled 20,449 hemagglutination inhibition and neutralization titers from 4,540 participants enrolled in 14 new vaccine studies we conducted and 50 prior studies that collectively span 2010-2023. Seasonal effects dominated, with pre- and post-vaccination titers declining steadily ...

12
Changes In Incidence And Serotype Distribution Of Pediat-Ric Invasive Pneumococcal Disease After The Introduction Of 15-Valent Pneumococcal Conjugate Vaccine In Catalo-Nia, Spain. A Multicenter Surveillance Study
2026-02-12 epidemiology 10.64898/2026.02.11.26346066
Top 0.2% (7.6%)
Show abstract

BackgroundSerotype 3 (S3) has remained a major cause of invasive pneumococcal disease (IPD) despite its inclusion in 13-valent pneumococcal conjugate vaccine (PCV). In October 2023, a 15-valent PCV (PCV15) including S3 was introduced into the Catalan universal childhood immunization program. MethodsWe conducted a retrospective pre-post surveillance study to compare pediatric IPD incidence in Catalonia during a pre-PCV15 period (October 1, 2022-September 30, 2023) and two post-PCV15 periods (Oct...

13
Respiratory syncytial virus infection and reinfection patterns during a community outbreak in Kenya investigated by whole genome sequencing, 2023/2024
2026-02-02 epidemiology 10.64898/2026.01.26.26343753
Top 0.2% (7.3%)
Show abstract

BackgroundRespiratory syncytial virus (RSV) is a leading cause of severe acute respiratory infection in infants, young children and vulnerable adults. Despite implications for designing interventions, our understanding of RSV infection/reinfection patterns during community outbreaks is incomplete. MethodsTo characterize respiratory virus infections regardless of symptom status, we performed a prospective cohort surveillance in coastal Kenya from August 2023 to August 2024. Nasopharyngeal/oropha...

14
The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes
2026-03-02 epidemiology 10.64898/2026.02.26.26347232
Top 0.3% (7.2%)
Show abstract

Dengue virus (DENV), comprising four distinct serotypes (DENV-1 to DENV-4), poses a major public health challenge in tropical regions. Infection with one serotype confers long-term immunity to that serotype alone, while subsequent heterologous infections are associated with increased risk of severe disease, necessitating vaccines that induce durable, balanced immunity across all serotypes. However, achieving such balance immunity remains a central challenge for dengue vaccine development. Using ...

15
TB and HIV Drive Distinct and Separate Tissue Resident Memory Cell Subset Depletion
2026-02-14 infectious diseases 10.64898/2026.02.12.26345105
Top 0.3% (7.2%)
Show abstract

BackgroundTuberculosis (TB) and HIV co-infection cause profound immune dysregulation. Understanding how these infections alter immune cell distribution across systemic and tissue compartments is critical for improving therapeutic and vaccine strategies. MethodsFlow cytometry was used to quantify CD4 and CD8 T cells, B cells, and tissue-resident memory (TRM) T and B cells in peripheral blood mononuclear cells (PBMCs), lung tissue, bronchoalveolar lavage (BAL), spleen, and lung-draining hilar lym...

16
Epstein Barr viral shedding dynamics in saliva during acute SARS-CoV-2 infection
2026-01-05 infectious diseases 10.64898/2025.12.31.25343091
Top 0.3% (7.0%)
Show abstract

BackgroundEpstein-Barr virus (EBV) establishes latency in most adults and can be reactivated under conditions of co-infection and immune dysregulation. COVID-19 has been associated with EBV reactivation, primarily in hospitalized cohorts, but EBV shedding in the oral cavity and the extent to which these dynamics trigger a systemic anti-EBV antibody response during acute COVID-19 remain poorly understood. MethodsWe conducted a nested cohort study of 69 community-based participants including 56 S...

17
Impact of SARS-CoV-2 exposure history on antibody kinetics and correlates of protection in The Gambia
2026-01-04 epidemiology 10.64898/2026.01.02.26343369
Top 0.3% (6.7%)
Show abstract

BACKGROUNDUnderstanding SARS-CoV-2 antibody dynamics is critical for pandemic preparedness, particularly where population immunity has developed through high infection rates with minimal vaccination. Whether predominantly asymptomatic infections confer protective immunity and which biomarkers best predict protection in resource-limited settings remain unclear. METHODSWe conducted a household cohort study in The Gambia over 15 months (March 2021-June 2022) during Delta and Omicron waves, with we...

18
Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies
2026-02-12 infectious diseases 10.64898/2026.02.10.26346014
Top 0.4% (6.6%)
Show abstract

Clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses continue to expand geographically and across mammalian hosts, raising concern about pandemic potential. The degree and specificity of pre-existing immunity in humans are key determinants of this risk. We analyzed hemagglutinin (HA)-and neuraminidase (NA)-specific antibody responses in 300 sera collected from adults in New York City. While HA directed binding antibodies to clade 2.3.4.4b H5 were low and hemagglutination-inhibiting a...

19
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study
2026-02-03 infectious diseases 10.64898/2026.01.31.26345293
Top 0.4% (6.5%)
Show abstract

To evaluate the impact of sex on acute SARS-CoV-2 infection, 668 participants from the ACTIV-2/A5401 study were followed over a 28-day period. A primary analysis was performed on the 469 participants who had quantifiable viral loads at baseline. Male and female participants had comparable nasal SARS-CoV-2 RNA levels at study entry and throughout follow-up. However, sex-specific differences in viral shedding emerged when stratified by duration of symptoms. In the first three days from symptom ons...

20
Reservoir and Phylogenetic Signatures Identify Distinct Subsets of HIV-1 Nonsuppressible Viremia
2026-02-06 hiv aids 10.64898/2026.02.05.26345678
Top 0.4% (6.4%)
Show abstract

In nonsuppressible HIV viremia (NSV), individuals have persistently detectable viral load despite adherence to [≥]2 fully active antiretroviral drugs. NSV represents an area of clinical uncertainty and an opportunity to understand the mechanisms of HIV persistence. We performed in-depth virologic characterization to identify distinct NSV phenotypes. We categorized participants into those who had persistent viremia after antiretroviral therapy (ART) initiation (primary NSV) and those who had N...